Chicago-based derivatives exchange Bitnomial has launched monthly futures contracts tied to Injective’s native token INJ, making it the first US-regulated derivatives product for the Web3 financial network. The supporting evidence appears in the cited X post.
The company confirmed the listing in an official announcement, with institutional clients gaining immediate access and retail traders expected to follow through Bitnomial’s Botanical platform within weeks.
The launch carries direct implications for a pending spot ETF application. Canary Capital filed for a staked INJ exchange-traded fund, and Cboe BZX Exchange submitted a corresponding rule change request to the US Securities and Exchange Commission.
Bitnomial’s listing now starts a six-month regulated trading track record, a threshold that figures into SEC listing rule requirements for spot crypto ETF approvals.
What the INJ Futures Contract Covers
The monthly futures contracts settle directly in INJ and allow traders to gain price exposure to the token without holding it outright. Margin can be posted in either cryptocurrency or US dollars through Bitnomial’s integrated clearinghouse, giving institutional desks flexibility in how they manage collateral.
Bitnomial said it also plans to expand the INJ product suite to include perpetual futures and options, broadening the available instruments for both hedgers and speculators.
That roadmap mirrors the exchange’s approach with other altcoin listings, where it has progressively deepened product coverage after establishing an initial futures market.
Injective operates a Layer 1 blockchain purpose-built for financial applications, featuring a fully on-chain order book and cross-chain connectivity to networks including Ethereum and Solana. Injective confirmed the Bitnomial listing on X, describing it as the token’s entry into US-regulated derivatives markets for the first time.
Bitnomial is regulated by the Commodity Futures Trading Commission and operates its own trading venue, clearinghouse, and brokerage under that oversight.
The exchange has positioned itself as one of the few US venues willing to build out regulated derivatives infrastructure for altcoins beyond Bitcoin and Ether, a segment of the market that has remained largely underdeveloped despite growing institutional demand.
Regulatory Wins and a Broader Altcoin Derivatives Push
The INJ listing is not Bitnomial’s first move into regulated altcoin futures. In January, the exchange launched monthly futures tied to Aptos, marking the first CFTC-regulated derivatives product for that token.
The Injective contract follows that same template and adds to a small but growing roster of regulated altcoin derivatives available to US traders and investors.
Bitnomial’s path to this point has not been without friction. In August 2024, the exchange attempted to list XRP futures through CFTC self-certification, but the SEC challenged the effort, arguing the contracts could fall under securities exchange registration requirements.
Bitnomial filed a lawsuit against the SEC in October 2025 and later dropped the case in March before successfully launching regulated XRP futures for US users the same month, citing a shift in SEC enforcement posture under evolving agency policy.
That sequence illustrates how much the regulatory climate has changed over the past year. What once required litigation to resolve is now moving through channels quickly enough for the exchange to list and expand altcoin derivatives products in rapid succession.
The INJ launch appears timed to take advantage of that window, particularly given the active ETF filing already sitting with the SEC.
Other major platforms have moved in parallel directions, though typically with larger assets.
Coinbase launched CFTC-regulated futures tied to Bitcoin and Ether for institutional clients in June 2023, expanded access with retail-sized contracts in May 2025, and introduced around-the-clock trading to serve US participants across time zones.
Kraken acquired futures platform NinjaTrader for roughly $1.5 billion in May 2025, gaining a CFTC-registered Futures Commission Merchant and a direct foothold in regulated derivatives.
Bitnomial occupies a distinct niche in that landscape. Rather than competing on Bitcoin and Ether volume, the exchange has concentrated on being the first regulated venue for emerging tokens with active communities and real on-chain utility.
Injective, with its DeFi-native architecture and cross-chain reach, fits that profile.
Whether Canary Capital’s ETF application ultimately advances will depend on SEC review, but the six-month futures track record that Bitnomial’s listing initiates is now formally underway, giving the filing a regulatory foundation it previously lacked.
Not Financial Advice: This article is for informational purposes only. Crypto investments are highly volatile. Always do your own research.
